Please ensure Javascript is enabled for purposes of website accessibility

Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion

By Cory Renauer - Mar 4, 2021 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.

On Thursday, Amgen (AMGN 0.87%) became the latest big drugmaker to announce an acquisition in 2021. The biotech giant told investors that it will acquire Five Prime Therapeutics (FPRX) for $1.9 billion in cash.

Five Prime Therapeutics is a clinical-stage biotech that doesn't have any approved products for sale yet. Amgen is eager to acquire it now for access to bemarituzumab, a potential first-in-class treatment for stomach cancer. 

People making a deal with a handshake.

Image source; Getty Images.

In a phase 2 trial with 155 patients, adding bemarituzumab to a standard chemotherapy regimen lowered patients' risk of death by 42% compared to standard chemo on its own. Bemarituzumab is a lonely member of a potential new class of cancer treatment that blocks the production of fibroblast growth factors. Among patients with tumor cells that overexpress bemarituzumab's target, FGFR2b, the survival benefit appeared even stronger.

In 2020, Amgen reported total revenue that grew 9% year over year, but a lack of new drugs emerging from its late-stage pipeline has investors worried that the company can't continue growing at this pace for much longer. The acquisition of Five Prime, which is expected to close by the end of the second quarter, adds a candidate ready to begin phase 3 trials, at a price Amgen can comfortably afford.

As a treatment for stomach cancers, there's a good chance that the investment in Five Prime will work out well for Amgen shareholders. It's still a long shot, but there's also a chance bemarituzumab could become an effective new treatment for a lot more cancer patients with tumors that it targets. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$255.26 (0.87%) $2.21
Five Prime Therapeutics, Inc. Stock Quote
Five Prime Therapeutics, Inc.
FPRX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.